Abeona Therapeutics announces Fast Track Designation from FDA for ABO-102
Abeona Therapeutics announced the FDA granted Fast Track designation for ABO-102, a single intravenous injection of AAV gene therapy for subjects with MPS IIIA, a rare autosomal recessive disease affecting every cell and organ in the body causing neurocognitive decline. October 25, 2016